By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics said this week that updated study data on its Septin9 biomarker had detected colorectal cancer cases with a sensitivity of 63 percent and specificity of around 89 percent. The German molecular diagnostics firm said that the results meet the targeted specificity range of 85 percent to 90 percent, which should support public and private payer coverage and reimbursement. The results met the firm's primary study objective.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.